TSE:TH Theratechnologies (TH) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free TH Stock Alerts C$1.85 +0.04 (+2.21%) (As of 04/22/2024 ET) Add Compare Share Share Today's RangeC$1.79▼C$1.8750-Day RangeC$1.64▼C$2.2952-Week RangeC$1.22▼C$5.84Volume5,600 shsAverage Volume38,321 shsMarket CapitalizationC$85.06 millionP/E RatioN/ADividend Yield3.76%Price TargetC$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Theratechnologies alerts: Email Address Theratechnologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside197.3% UpsideC$5.50 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 stars 3.3 Analyst's Opinion Consensus RatingTheratechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTheratechnologies has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for TH. Previous Next 1.7 Dividend Strength Dividend LeadershipTheratechnologies is a leading dividend payer. It pays a dividend yield of 3.76%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthTheratechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TH. Previous Next 2.8 News and Social Media Coverage News SentimentTheratechnologies has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Theratechnologies this week, compared to 1 article on an average week.Search Interest2 people have searched for TH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theratechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.29% of the stock of Theratechnologies is held by insiders.Percentage Held by Institutions50.88% of the stock of Theratechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Theratechnologies is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theratechnologies is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Theratechnologies, their PEG ratio cannot be calculated. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About Theratechnologies Stock (TSE:TH)Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More TH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TH Stock News HeadlinesApril 23, 2024 | americanbankingnews.comTheratechnologies (TSE:TH) Stock Price Passes Below 50 Day Moving Average of $1.95April 15, 2024 | americanbankingnews.comFY2024 EPS Estimates for Theratechnologies Inc. (TSE:TH) Raised by AnalystApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 14, 2024 | theglobeandmail.comTheratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)April 10, 2024 | msn.comU.S. Index Futures Show Mixed Trend Ahead of Key Inflation Data Release, Oil Prices Edge HigherApril 9, 2024 | stockhouse.comTheratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology(TM) Oncology PlatformMarch 11, 2024 | msn.comNurse-Led Strategy Reduces Cardiovascular Risk Factors for People With HIVFebruary 27, 2024 | morningstar.comTheratechnologies Shares Sink Premarket After FDA Refusal to File LetterApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 27, 2024 | seekingalpha.comTheratechnologies stock plunges after FDA denies review of Trogarzo sBLAFebruary 23, 2024 | finance.yahoo.comTheratechnologies Full Year 2023 Earnings: Misses ExpectationsFebruary 21, 2024 | finance.yahoo.comTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 GuidanceFebruary 21, 2024 | markets.businessinsider.comHere's what Wall Street expects from Theratechnologies's earnings reportFebruary 20, 2024 | benzinga.com7THTX : Theratechnologies Earnings PreviewFebruary 20, 2024 | finance.yahoo.comTheratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of ActionFebruary 6, 2024 | finance.yahoo.comTheratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateJanuary 31, 2024 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Theratechnologies StockJanuary 25, 2024 | msn.comFDA denies approval for Theratechnologies’ tesamorelin F8January 24, 2024 | marketwatch.comTheratechnologies: FDA Rejects Newer Egrifta FormulationJanuary 24, 2024 | marketwatch.comTheratechnologies Shares Slide Premarket as FDA Turns Away Newer EgriftaJanuary 24, 2024 | markets.businessinsider.comTheratechnologies Stock Falls On CRL From FDA For F8 Formulation Of TesamorelinJanuary 24, 2024 | marketwatch.comTheratechnologies Shares Sink at Open After FDA Rejects Newer Tesamorelin FormulationJanuary 24, 2024 | finance.yahoo.comTheratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLAJanuary 23, 2024 | marketwatch.comTheratechnologies Shares Fall as FDA Continues to Review License Application for TesamorelinJanuary 23, 2024 | msn.comTheratechnologies stock slides as Egrifta review runs beyond FDA target dateJanuary 23, 2024 | markets.businessinsider.comTheratechnologies Says FDA Needs More Time To Decide On Tesamorelin F8 SBLAJanuary 2, 2024 | finanznachrichten.deTheratechnologies Submits sBLA for Trogarzo Intramuscular (IM) Method of Administration to FDASee More Headlines Receive TH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/23/2024Next Earnings (Estimated)7/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:TH CUSIPN/A CIKN/A Webwww.theratech.com Phone+1-514-3367800FaxN/AEmployees103Year FoundedN/APrice Target and Rating Average Stock Price TargetC$5.50 High Stock Price TargetC$5.50 Low Stock Price TargetC$5.50 Potential Upside/Downside+197.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.24) Trailing P/E RatioN/A Forward P/E Ratio50.35 P/E Growth-8.5Net IncomeC$-23,960,000.00 Net Margins-29.30% Pretax MarginN/A Return on Equity-1,116.86% Return on Assets-6.33% Debt Debt-to-Equity Ratio562.07 Current Ratio1.34 Quick Ratio0.64 Sales & Book Value Annual SalesC$81.76 million Price / Sales1.04 Cash FlowC$0.49 per share Price / Cash Flow3.76 Book ValueC($0.45) per share Price / Book-4.11Miscellaneous Outstanding Shares45,980,000Free FloatN/AMarket CapC$85.06 million OptionableNot Optionable Beta1.73 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Paul Lévesque (Age 59)President, CEO & Director Comp: $1.6MMr. Philippe Dubuc M.B.A. (Age 57)MBA, Senior VP & CFO Comp: $587.17kMr. Jocelyn Lafond L.L.M. (Age 56)LL.B., General Counsel & Corporate Secretary Comp: $429.6kDr. Christian Marsolais Ph.D. (Age 61)Senior VP & Chief Medical Officer Comp: $590.29kMr. John Leasure (Age 59)Global Commercial Officer Comp: $571.68kHon. Andre Dupras M.Sc. (Age 60)Vice President of Human Resources More ExecutivesKey CompetitorsIntelGenx TechnologiesCVE:IGXNovoheartCVE:NVHPediapharmCVE:PDP138267 (COM.TO)TSE:COMScythian BiosciencesCVE:SCYBView All CompetitorsInsidersDale WeilBought 36,200 shares on 11/1/2023Total: C$49,956.00 ($1.38/share)Joseph ArenaBought 10,000 shares on 10/30/2023Total: C$9,250.00 ($0.93/share)Dawn SvoronosBought 15,800 shares on 10/27/2023Total: C$21,646.00 ($1.37/share)Philippe DubucBought 8,000 shares on 10/27/2023Total: C$10,855.20 ($1.36/share)View All Insider Transactions TH Stock Analysis - Frequently Asked Questions Should I buy or sell Theratechnologies stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TH shares. View TH analyst ratings or view top-rated stocks. What is Theratechnologies' stock price target for 2024? 2 brokerages have issued 1 year target prices for Theratechnologies' stock. Their TH share price targets range from C$5.50 to C$5.50. On average, they anticipate the company's share price to reach C$5.50 in the next twelve months. This suggests a possible upside of 197.3% from the stock's current price. View analysts price targets for TH or view top-rated stocks among Wall Street analysts. How have TH shares performed in 2024? Theratechnologies' stock was trading at C$2.14 at the beginning of 2024. Since then, TH stock has decreased by 13.6% and is now trading at C$1.85. View the best growth stocks for 2024 here. When is Theratechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our TH earnings forecast. How were Theratechnologies' earnings last quarter? Theratechnologies Inc. (TSE:TH) announced its earnings results on Wednesday, February, 21st. The company reported ($0.11) earnings per share for the quarter. The company earned $31.93 million during the quarter. Theratechnologies had a negative net margin of 29.30% and a negative trailing twelve-month return on equity of 1,116.86%. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Nemaska Lithium (NMX), Shopify (SHOP), United Therapeutics (UTHR) and Avigilon (AVO). How do I buy shares of Theratechnologies? Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:TH) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
